| 2019-05-13 06:05:48|
CPRX 06:05 05/13 05/13/19
Catalyst Pharmaceuticals reports Q1 EPS (1c), may not compare to consensus (13c)
Reports Q1 revenue $12.4M, may not compare to consensus $1.6M. "The first quarter of this year was very critical for us, as we became a fully-integrated biopharmaceutical company with the commercial launch of Firdapse," said Patrick McEnany, Chairman and CEO of Catalyst Pharmaceuticals. "We are pleased that the Firdapse launch is off to an excellent start and while it is still early, with much work to be done, it is especially gratifying to see the number of patients that were previously naive to any form of amifampridine that are now being effectively treated with Firdapse. We continue to be motivated by the very positive response that we are receiving from patients and healthcare providers. Lastly, we continue to make progress in clinical development of our robust pipeline of other potential indications for Firdapse."